37,889 research outputs found
Ralf Martin & John van Reenen. The case for a COVID-19 carbon tax
No full textRalf Martin and John Van Reenen (LSE) explain how a carbon tax could both help pay for the enormous costs of the pandemic and encourage ‘clean’ investment. Crucially, it should be levied in a few years’ time, when the UK economy has begun to recover
In brief: Saving the economy and the planet
No full textThe economic crisis may offer an opportunity to set the world on the right track for addressing climate change, writes Ralf Martin.
Wissenschaftliches Kolloquium aus Anlass des 70. Geburtstages von Prof. Dr. Fritz Loos am 23. Januar 2009
No full textDer vorliegende Band enthält die auf dem Kolloquium am 25. April 2009 von Klaus Geppert, Ralf Krack und Günter Jakobs gehaltenen Vorträge und wird ergänzt durch Beiträge, die frühere und jetzige Göttinger Kollegen von Fritz Loos zu seinen Ehren verfasst haben. Die einzelnen Aufsätze versuchen mit den Generalthemen Grundfragen des Strafrechts, Rechtsphilosophie und der (unendlichen) Reform der Juristenausbildung einen Teil der Arbeitsschwerpunkte des Jubilars abzudecken. Mit dem Tagungsband verfolgen die Herausgeber das Anliegen, den Lehrer und Wissenschaftler Fritz Loos in möglichst vielen Facetten seiner Person zu würdigen und als seine akademischen Schüler Dank zu sagen für die Förderung, die er uns hat zukommen lassen
Clean technologies for growth and equity
No full textPublic investment in developing energy sources that don’t cause climate change is a strategy for economic growth that could also contribute to the UK’s levelling up agenda, says Ralf Martin. His analysis indicates that subsidies for research and development in ‘clean’ technologies can bring returns more than 40% higher than average
Setting priorities, pooling resources and accelerating transformation : new approaches in industrial and technology policy
No full textHeike Belitz, Martin Gornig, Claudia Kemfert, Ralf Löckener, Torsten Sundmache
How hoax information on social media about Covid-19 might be worsening the pandemic
No full textInformation claiming that the COVID-19 is a hoax has unfolded on social media at the same time as the virus has spread across the world. Ralf Martin has analysed nearly 12 million tweets for spikes in COVID-19 hoax related content. He finds that those posting coronavirus related hoax content are more likely to mention Donald Trump, and that many areas where hoaxism is prevalent, like New York,also have higher infection rates
Prioritäten setzen, Ressourcen bündeln, Wandel beschleunigen : neue Ansätze in der Industrie- und Technologiepolitik
No full textHeike Belitz, Martin Gornig, Claudia Kemfert, Ralf Löckener, Torsten SundmacherLiteraturverzeichnis Seite 33-3
Portable EEG in groups shows increased brain coupling to strong health messages
No full textThis project contains data and supplementing material to the Study "Portable EEG in groups shows increased brain coupling to strong health messages" authored by Martin A. Imhof, Karl-Philipp Flösch, Ralf Schmälzle, Britta Renner, & Harald T. Schupp.
Contact: [email protected] [email protected]
Martha Friedenthal-Haase / Ralf Koerrenz (Hrsg.): Martin Buber. Bildung, Menschenbild und Hebräischer Humanismus. Paderborn, München, Wien, Zürich: Ferdinand Schöningh 2005 (263 S.) [Rezension]
No full textRezension von: Martha Friedenthal-Haase / Ralf Koerrenz (Hrsg.): Martin Buber. Bildung, Menschenbild und Hebräischer Humanismus. Paderborn, München, Wien, Zürich: Ferdinand Schöningh 2005 (263 S.; ISBN 3-506-71790-1; 29,90 EUR)
High-dose intravenous immunoglobulins in the treatment of multiple sclerosis. An update
No full textThe immunomodulatory treatment of multiple sclerosis (MS) with high-dose intravenous immunoglobulins (IVIg) has been discussed with some controversy in the context of evidence-based medicine. The recent publication of eight trials investigating several aspects of MS has shed some more light on the role of IVIg treatment in MS. Here we summarize and critically discuss the new data in the context of previous studies on this treatment. In relapsing-remitting MS, IVIg remain a second-line treatment when other licensed treatments are not possible. Currently there is no role for IVIg in secondary progressive MS. Similarly, the use of IVIg during an acute relapse shows no benefit in addition to standard steroid treatment. The initiation of IVIg therapy after a clinically isolated syndrome has delayed the occurrence of definite MS, and this may become a new indication. Furthermore, previous data suggesting that IVIg can reduce the incidence of postpartal relapses have been substantiated. However, those trials unfortunately lack appropriate internal control groups. By and large, previous recommendations for the use of IVIg in MS are supported by the new data
- …
